<DOC>
	<DOC>NCT02690181</DOC>
	<brief_summary>The objective of this extension study is the initial assessment of safety and immunogenicity of the second dose of GBS Trivalent Vaccine following the time interval that is close to the inter-pregnancy interval observed in the general population.</brief_summary>
	<brief_title>Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>1. Healthy, nonpregnant subjects who have received a single 5 µg dose of GBS Trivalent Vaccine or placebo in the V98_06 study and healthy nonpregnant female subjects aged 2246 years inclusive on the day of informed consent who have not received any GBS vaccine in the past 2. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator 3. Females of childbearing potential who are using an effective birth control method which they intend to use until the end of the study (day 181 visit) or females of nonchildbearing potential 1. Progressive, unstable or uncontrolled clinical conditions, or clinical conditions representing a contraindication to intramuscular vaccination and blood draws 2. Abnormal function of the immune system 3. Received immunoglobulins or any blood products within 180 days prior to informed consent 4. Received an investigational or nonregistered medicinal product within 30 days prior to informed consent 5. Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study 6. Individuals who received any other vaccines within 14 days for inactivated vaccines or 28 days for live vaccines prior to enrolment in this study or who are planning to receive any vaccine within 28 days from the study vaccination. Exception an inactivated influenza vaccine may be administered up to 7 days prior to study vaccination or 7 days after study vaccination 7. Individuals who anticipate becoming pregnant prior to the end of the study, or individuals who are breastfeeding 8. Individuals who have had a previous immunization with a vaccine containing Group B Streptococcus antigens that was not part of V98_06 study 9. Individuals with a fever (oral temperature ≥ 38°C) within 3 days prior to day 1 or use of antipyretics and/or analgesic medications within 24 hours prior to day 1 10. Individuals with acute or chronic infection(s) that require systemic antibiotic treatment or antiviral therapy, within 7 days prior to day 1</criteria>
	<gender>Female</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>